The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The objective of this study is to analyze the in vivo behavior of the (177)Lu-labeled peptides DOTATATE, DOTANOC, and DOTATOC used for peptide receptor radionuclide therapy (PRRNT) of neuroendocrine tumors (NETs), by measuring organ and tumor kinetics and by performing dosimetric calculations.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Recent Results Cancer Res.

Title: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

ISSN: 0080-0015

ISSN (Print): 0080-0015

Publication date (Electronic): 2013

Volume: 194

Affiliations

[1 ] Department of Nuclear Medicine, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany.

Article

DOI: 10.1007/978-3-642-27994-2_30

PubMed ID: 22918780

SO-VID: 33a2979a-f566-43ba-be18-d03be1481db6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 14

See all cited by